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Background: Low-intensity shock wave (SW) therapy (SWT) has been shown to improve symptoms and exercise tolerance in patients (pts.) with 
coronary artery disease (CAD). Induction of neovascularization and improvement of myocardial perfusion are mechanisms suspected in this context.
Methods: 16 pts. with advanced CAD (mean age 66±10 years) not suitable for revascularization who were suffering from severe chronic angina 
pectoris (CCS class III or IV) refractory to individually optimized medical treatment underwent a series of 9 echocardiography-targeted SW 
applications (3 sessions per week; weeks 1, 5, and 9). The antero-septal wall (LAD territory) was targeted in 9, the lateral wall (RCX territory) in 5, 
and the inferior wall (RCA territory) in 2 pts.. A series of 300-500 shocks was applied per session. Anti-anginal medication (combination of 2 or 3 
drugs) was kept unchanged. Regional myocardial blood flow (MBF) and coronary flow reserve were measured quantitatively by NH3-PET at baseline 
and 4 weeks after completion of SWT.
Results: At follow-up, 14 pts. (88%) reported improvement of angina to a tolerable level. CCS angina class decreased from 3.1±0.7 to 2.4+0.6 
(p=0.0004). Maximum ergometric workload increased from 80±45 to 90±39 watts (p=0.04), the double product (heart rate x systolic blood 
pressure) from 14676±4400 to 16460±5006 (p=0.2). MBF in the LV region targeted by SWT improved from 95±30 mL/min/100g at baseline to 
114±50 mL/min/100g at follow up (p=0.04), while there was no change in the opposite wall (115±45 vs. 113±48 ml/min/100g; p=0.9).
Conclusions: SWT improves symptoms in pts. with chronic refractory angina pectoris. Regional improvement of MBF in the region targeted by 
SWT was also documented by PET imaging. Additional studies with more pts. are warranted to clarify the role of SWT in the armamentarium for this 
difficult-to-treat pat. group.
